Genor Biopharma Holdings (FRA:67N0) Net Margin %: -168.30% (As of Jun. 2025)


FRA:67N0 Genor Biopharma Holdings Ltd FRA:67N0
22 GF Score
Price €0.34
! 1 Warning Sign
View Full Analysis

What is Genor Biopharma Holdings Net Margin %?

Genor Biopharma Holdings FRA:67N0 +3.70% 22 Net Margin % is -168.30% as of Jun. 2025. GuruFocus rates FRA:67N0 with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Net margin is calculated as Net Income divided by its Revenue. Genor Biopharma Holdings's Net Income for the six months ended in Jun. 2025 was €-6.55 Mil. Genor Biopharma Holdings's Revenue for the six months ended in Jun. 2025 was €3.89 Mil. Therefore, Genor Biopharma Holdings's net margin for the quarter that ended in Jun. 2025 was -168.30%.

The historical rank and industry rank for Genor Biopharma Holdings's Net Margin % or its related term are showing as below:

FRA:67N0' s Net Margin % Range Over the Past 10 Years
Min: -29292.61   Med: -4184.87   Max: 15.01
Current: 15.01

FRA:67N0's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -88.815 vs FRA:67N0: 15.01

Genor Biopharma Holdings  (FRA:67N0) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Genor Biopharma Holdings Net Margin % Related Terms

Genor Biopharma Holdings Net Margin % Historical Data

* Premium members only.

The historical data trend for Genor Biopharma Holdings's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genor Biopharma Holdings Net Margin % Chart

Genor Biopharma Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
Get a 7-Day Free Trial -29,292.61 0.00 -4,583.87 0.00 -24.87

Genor Biopharma Holdings Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -929.25 43.38 -168.30

FRA:67N0 vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Genor Biopharma Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genor Biopharma Holdings Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's Net Margin % distribution charts can be found below:

* The bar in red indicates where Genor Biopharma Holdings's Net Margin % falls into.


FRA:67N0
22GF Score
Genor Biopharma Holdings Ltd FRA:67N0
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genor Biopharma Holdings Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Genor Biopharma Holdings's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-6.727/27.051
=-24.87 %

Genor Biopharma Holdings's Net Margin for the quarter that ended in Jun. 2025 is calculated as

Net Margin=Net Income (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-6.552/3.893
=-168.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -168.30% mean?
Genor Biopharma Holdings (FRA:67N0) has a Net Margin % of -168.30% as of Jun. 2025. Net margin is the ratio of total net income to net sales. View historical data on Genor Biopharma Holdings and its competitors.
Is Genor Biopharma Holdings' Net Margin % too high?
Genor Biopharma Holdings' current Net Margin % is -168.30%. Overall, Genor Biopharma Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Genor Biopharma Holdings' Net Margin % compare to VRTX and REGN?
Genor Biopharma Holdings' Net Margin % of -168.30% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Genor Biopharma Holdings and its competitors. Genor Biopharma Holdings's current Net Margin % is -168.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genor Biopharma Holdings stock overvalued right now?
Genor Biopharma Holdings (FRA:67N0) has a current Net Margin % of -168.30%. The current Net Margin % is -168.30%. Genor Biopharma Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Genor Biopharma Holdings (FRA:67N0), the current Net Margin % is -168.30% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genor Biopharma Holdings Business Description

Address 690 Bibo Road, Room 501-02, Building 6, Pudong New District, Shanghai, CHN, 201203
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
22GF Score

Get the complete analysis for FRA:67N0

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.34
Price